Research programme: Dual-Affinity Re-Targeting anticancer therapeutics - MacroGenicsAlternative Names: DART candidates - MacroGenics/Pfizer; DART Oncology; EphA2xCD3 DART; IL1Ra2xCD3 DART; MGD 013; MGD-15; ROR1xCD3 DART
Latest Information Update: 05 Aug 2016
At a glance
- Originator MacroGenics
- Class Bispecific antibodies; Proteins
- Mechanism of Action CD223 antigen inhibitors; CD3 antigen modulators; Interleukin 13 receptor modulators; PDCD 1 protein inhibitors; Receptor tyrosine kinase-like orphan receptor modulators; T lymphocyte stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer